Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.
A number of consumer genetic testing companies are adopting best practice guidelines for customer privacy, the Washington Post reports.
A panel led by the FH Foundation recommends routine genetic testing for those with very high LDL cholesterol and a family history of high cholesterol or early heart attack.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.
The guidelines are the first to attempt to specify which drugs are appropriate to test for routinely, guideline authors say.
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
Agendia said that the guidelines reflect MammaPrint's rank as the only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT clinical trial.
Harvard researchers call for a discussion and development of guidelines for 'embryoid' research, NPR reports.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.